ReviewAdvances in experimental medicine and biology2024
IL-6 Blockade in Cytokine Storm Syndromes.
Review in Advances in experimental medicine and biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Whole-body cryotherapy can reduce the inflammatory response in humans: a meta-analysis based on 11 randomized controlled trials.Scientific reports · 2025Pooled it
- Dexmedetomidine reduces the inflammation level and morality in adult sepsis: a systemic review and meta-analysis based on randomized controlled trials.Frontiers in medicine · 2025Pooled it
- Development of CAR Exosomes Targeting FAP for the Treatment of Intrauterine Adhesion.Journal of extracellular vesicles · 2026Article
- IL-6 regulates the polarization of Dectin-1 macrophages to weaken immune escape in thyroid cancer.Journal of translational medicine · 2026Article
- Interleukin-6-to-lymphocyte ratio as a novel prognostic factor in patients with severe fever with thrombocytopenia syndrome: a discovery and validation study.Frontiers in immunology · 2026Article
- MGAT5 regulates ferroptosis via the Nrf2/HO-1 signaling pathway in diabetic nephropathy.Open life sciences · 2026Article
- Inter-organ crosstalk in systemic inflammation: a narrative review of molecular mechanisms and pharmacological modulation in the muscle-adipose-liver axis.Frontiers in pharmacology · 2026Review
- CD3-CSPG4 bispecific T cell engager: A novel platform for malignant melanoma therapy.PloS one · 2026Article
- Ganglioside therapy in cancer molecular insights and therapeutic opportunities.Discover oncology · 2025Review
- Prediction of Hyperinflammatory Phenotypes in Critically Ill Patients via Routine Clinical Data and IL-6: Towards Personalized Anti-Inflammatory Therapy.International journal of molecular sciences · 2025Article
- Balancing Host Defense and Viral Tolerance for the Development of Next-Generation Broad-Spectrum Antiviral Agents.Pathogens (Basel, Switzerland) · 2025Review
- Adult Long Coronavirus Disease 2019: Definition, Prevalence Pathophysiology, and Clinical Manifestations.Infectious disease clinics of North America · 2025Review
- Degradation of WE43 Magnesium Alloy in Vivo and Its Degradation Products on Macrophages.ACS omega · 2025Article
- Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers.ESMO open · 2025Article
- Anti-Inflammatory Action and Molecular Mechanism of Fucoidan Against Cystitis Glandularis.Food science & nutrition · 2024Article
- Comparison between traditional logistic regression and machine learning for predicting mortality in adult sepsis patients.Frontiers in medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-6 (IL-6) is a pro-inflammatory cytokine elevated in cytokine storm syndromes, including hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS). It is also elevated in cytokine release syndrome (CRS) after immune activating cancer therapies such as chimeric antigen receptor (CAR) T-cells or bispecific T-cell engagers (BITEs) and in some patients after infection with SARS-CoV-2. The interaction of IL-6 with its receptor complex can happen in several forms, making effectively blocking this cytokine's effects clinically challenging. Fortunately, effective clinical agents targeting the IL-6 receptor (tocilizumab) and IL-6 directly (siltuximab) have been developed and are approved for use in humans. IL-6 blockade has now been used to safely and effectively treat several cytokine storm syndromes (CSS). Other methods of investigation in effective IL-6 blockade are underway.
Indexed as
Identifiers
39117839What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.